FDA grants approval to third-generation VERO Biotech GENOSYL delivery system

The FDA has approved US-based medical equipment supplier VERO Biotech’s new-generation tankless inhaled nitric oxide (iNO) delivery system. This new device is hoped to reduce storage constraints while still operating at maximum efficiency.

GENOSYL ‒ nitric oxide for inhalation ‒ is used for neonates (newborn babies under four weeks old) with hypoxic respiratory failure related to pulmonary hypertension, along with ventilatory support. Inhaled nitric oxide dilates the pulmonary blood vessels, which improves oxygenation.

The GENOSYL delivery system (DS) enables simplified workflow through many features, coming with an adaptive sensor and automated cassette activation which enables rapid dosing by speeding up the time to achieve the desired dose. Its dual cassette bay enables clinicians to work from one console, transitioning the cassettes automatically for ease of use.

According to VERO Biotech, GENOSYL DS is the first tankless inhaled nitric oxide delivery system approved in the US.

VERO Biotech CEO and president Brent V Furse commented, “The continuous innovation of the GENOSYL Delivery System represents our commitment to neonatal intensive care and the acute care hospital community in providing solutions to the challenges they face. We are grateful for the partnership and support we received with the launch of our innovative tankless GENOSYL Delivery System and this collaboration that has and will allow VERO Biotech to continue to expand on its mission to save lives, alleviate suffering and improve the health economics of acute care.”

James Spargo